Question · asked by 1 review
Radioembolisation plus sorafenib vs sorafenib monotherapy: All‐cause mortality at 1 year
- Population
- people with hepatocellular carcinoma
- Intervention
- Radioembolisation plus sorafenib
- Comparison
- sorafenib monotherapy
- Outcome
- All‐cause mortality at 1 year
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Radioembolisation plus sorafenib vs sorafenib monotherapy All‐cause mortality at 1 year · people with hepatocellular carcinoma The review found no eligible studies for this question. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (2020) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.